Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

Abbott Laboratories ABT presented late-breaking clinical data that demonstrate the FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor. The results were presented at the ...

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...